Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin-17A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study is to assess longterm efficacy and safety of secukinumab for 52 weeks in real-world clinical practise in our facility. A total of 83 patients (71 with psoriasis vulgaris and 12 with psoriatic arthritis) were included, and 49 of them were bioswitched patients. Psoriasis Area and Severity Index (PASI) 75 and PASI-90 responses were 80% and 64% at week 12, 77% and 65% at week 24, and 76% and 58% at week 52, respectively. No significant differences were observed in efficacy between bio-naive and bio-switched patients. Arthralgia showed improvement by week 12 in all patients with psoriatic arthritis with a reduction of serum C-reactive protein level. Treatment was discontinued in 22% (18/83), including eight patients with no improvement or exacerbation of cutaneous manifestations, one patient with new onset of arthritis and two patients with transient infection. Overall, secukinumab showed a sustained clinical response with an acceptable safety profile through week 52 in Japanese psoriatic patients.
INTRODUCTION
Secukinumab is a recombinant, fully human immunoglobulin G1j monoclonal antibody that selectively binds to interleukin (IL)-17A and neutralizes its bioactivity. In Japan, it was approved in 2014 for the treatment of moderate to severe psoriasis vulgaris (PsV), psoriatic arthritis (PsA) and generalized pustular psoriasis. 1 Its excellent efficacy was demonstrated in clinical trials compared with those of placebo, etanercept or ustekinumab. [1] [2] [3] [4] [5] In Japanese patients receiving 300 mg secukinumab, Psoriasis Area and Severity Index (PASI)-75, -90 and -100 responses were achieved by 83%, 62% and 28% at week 12, respectively, and sustained up to week 52. 6 However, aside from clinical trials, secukinumab has not yet been sufficiently assessed in daily clinical practise for psoriatic patients.
In this report, we retrospectively analyzed long-term efficacy and safety of secukinumab in real-world clinical practise in our facility.
CASE REPORT Patients
Japanese male and female patients aged 20 years or more with the diagnosis of PsV or PsA, and who started treatment with secukinumab between May 2015 and August 2016 at the Department of Dermatology, The Jikei University School of Medicine, were all included in this retrospective study and followed for 52 weeks. The diagnosis was based on medical records, clinical findings and also histopathological findings if necessary.
Treatments
Secukinumab was administrated via s.c. injection (300 mg) at week 0, 1, 2, 3 and 4 as initial loading regimen and thereafter every 4 weeks. Some minor variations were allowed. Patients who skipped or shortened the initial loading regimen were also included.
Assessment of efficacy
The severity of cutaneous manifestations was evaluated using the PASI score at week 0, week 12 (range, 12-16), week 26 (range, 24-30) and week 52 (range, 50-54). Clinical efficacy was evaluated using PASI-50, -75, -90 and -100 responses at each time point. For PsA patients, serum C-reactive protein (CRP) was evaluated before treatment and at week 12 (range 12-16), and Visual Analog Scale (VAS) was measured at week 0 and week 12.
Safety assessments
Adverse events were assessed at each visit, and laboratory examinations and vital signs were checked periodically.
Statistical analysis
Data were expressed as mean AE standard deviation. Statistical analysis was performed using STATA software (Lightstone, Tokyo, Japan). P < 0.05 was considered statistically significant.
Patient results
A total of 83 patients (71 PsV, 12 PsA) were included in this study. Two patients were excluded for failure to visit the hospital after the initial injection. The baseline demographics and background characteristics are shown in Table 1 . The male : female ratio was 57:26, reflecting the male predominance of the Japanese psoriatic population, and age ranged 21-89 years (mean, 57.3 AE 15.2). Forty-nine patients were bioswitched to secukinumab from other biologics (nine from infliximab, 14 from adalimumab and 26 from ustekinumab). The other 34 patients were bio-naive, and they included 20 patients who switched from other systemic medications (12 from cyclosporin, one from etretinate and seven from narrowband ultraviolet B phototherapy), while five patients received topical treatment alone and nine patients had received no medication.
Five patients who switched from other biologics skipped or shortened the initial loading regimen according to the discretion of the prescriber.
Efficacy
In the combined PsV and PsA patients, the PASI score at baseline (week 0) ranged 0-32.4 (mean, 9.3 AE 6.8). After administration of secukinumab, the mean PASI score declined rapidly to 1.3 AE 3.4 at week 12 (P < 0.001), and by LOCF analysis, it was maintained at 1.3 AE 3.3 at week 24 (P < 0.001) and 1.5 AE 3.4 at week 52 (P < 0.001). The actual observed numbers were 83 at week 0, 83 at week 12, 75 at week 24 and 65 at week 52. Time-course changes of PASI-50, -75, -90 and -100 responses are shown in Figure 1 (a). The baseline PASI score of bio-naive patients was significantly higher compared with that of bio-switched patients (11.7 AE 7.2 vs 7.7 AE 5.3, P < 0.05). No significant differences in PASI-75 and -90 responses were found between the two groups after treatment at week 12, week 24 and week 52, although numerically higher responses were observed in the bio-switched group (Fig. 1b,c) . The PASI improvement rate had no correlation with body mass index, disease duration or a history of smoking by multivariate analysis (data not shown). Among 12 PsA patients, the reduction rate of VAS score at week 12 was less than 50% in three patients, 51-99% in four patients and 100% in five patients. No patient experienced worsening of pain at week 12. Indeed, compared with that at baseline, serum CRP level decreased significantly at week 12 (1.7 AE 2.5 vs 0.2 AE 0.5, P < 0.05).
Clinical course assessments and safety
There were no new or unexpected safety findings throughout the observation period. Of the enrolled 83 patients, mucosal Candida infection occurred in two patients (2.4%). No cases of neutropenia, inflammatory bowel disease or tuberculosis were observed. Eighteen patients (22%) discontinued treatment with secukinumab by week 52, namely eight patients (week 12-24) and 10 patients (after week 24). The reason for discontinuation was as follows: no improvement or exacerbation of cutaneous manifestations (8/18, 44%); failure to visit the hospital (6/18, 33%); new onset of arthritis (1/18, 6%); chronic pigmented purpura (1/18, 6%); and infection (2/18; 11%) including cellulitis on the foot and upper respiratory tract infection, both of which recovered afterwards.
As shown in Figure 2 , there was a gradual time-dependent decline of the drug survival rate in PsV patients. In PsA patients, the drug survival rate was initially higher, but the final survival rate was not different from that in PsV patients. Comparison of the drug survival rate between the bio-naive group and bio-switched group showed no significant difference.
DISCUSSION
In this study, not only PASI-75, but also the more stringent goals of PASI-90 and -100 responses showed a favorable outcome after treatment with secukinumab comparable with those achieved in clinical trials. [1] [2] [3] [4] [5] [6] In particular, responses at week 12
were sustained through week 52 in the majority of patients. This observation may in part reflect minimal immunogenicity of secukinumab. 7 Furthermore, we demonstrated the benefit of bio-switch from tumor necrosis factor (TNF)-a antagonists or IL-12/23 p40 antagonist, in accordance with the result of a randomized clinical trial in Japan. 6 However, in the postmarketing study to evaluate efficacy of direct switching to secukinumab from cyclosporin, response rates were lower in patients previously exposed to other biologics. 8 In our observation, direct bio-switched patients showed numerically higher response rates than bio-naive patients. Although the reason for this discrepancy is unknown, a proportion of bio-switched patients started secukinumab before obvious flare of cutaneous manifestations, and consequently five out of 49 patients even skipped or shortened the initial loading protocol of secukinumab. The effective regimen of bio-switch merits further investigation. Secukinumab was also shown to improve joint symptoms. In most PsA patients, arthralgia improved within 12 weeks, and serum CRP level was significantly decreased from the baseline accordingly. In fact, although TNF-a inhibitors are the mainstay treatment for PsA patients, IL-17A antagonists may be considered in certain situations, 9 as also supported by our study.
However, one PsV patient showed new onset of arthritis at week 41. It remains to be elucidated whether secukinumab may indeed block the progression of bone destruction.
Finally, secukinumab had a favorable safety profile consistent with that in previous trials. 10 IL-17A plays a key role in mucocutaneous defense against extracellular fungi and bacteria, and non-serious skin/mucosal candidiasis may occur dosedependently. Mucosal candidiasis was also found in our study, but recovered with topical antifungal agents. To conclude, both the high efficacy and safety of secukinumab were demonstrated over a period of 52 weeks in psoriatic patients in daily clinical practise. Although the sample size was small, and the study design was retrospective and observational, our present study confirms the usefulness of secukinumab in real-world clinical practise. 
